• AAPL 194.3134
  • TSLA 240.9644
  • AMZN 146.9523
  • BTC-USD 43168.9883
  • ETH-USD 2333.1021
  • EURUSD 1.0801
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. PHMMF.US

Pharma Mar SAU (PHMMF PINK) stock market data APIs

$35.81 0(0%) as of December 6, 2023

Pharma Mar SAU Financial Data Overview

35.81
35.81
-
35.81
35.81
32.095-69.1673
754 M
42.1294
17 726 K
168 M
0.092
0.0196
0.07
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PHMMF',
Type: 'Common Stock',
Name: 'Pharma Mar SAU',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00BBVVVW6',
ISIN: 'ES0169501022',
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: NULL,
IsDelisted: false,
}

Pharma Mar SAU Fundamental Data is available in our Financial Data APIs

  • Net Revenue 168 M
  • EBITDA 11 065 K
  • Earnings Per Share 0.85
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Pharma Mar SAU Earnings via APIs

  • Latest Release 2023-09-30
  • EPS/Forecast NaN

Get Pharma Mar SAU End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Pharma Mar SAU latest news via APIs

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

- The final results of the APLICOV-PC study (Phase I-II), which were initially released last May and which the Company shared with the scientific community, demonstrate the safety of plitidepsin's use...
  • EUROPEAN MOLECULAR BIOLOGY ORGANIZATION
  • LIFE SCIENCE ALLIANCE
  • OMICRON
  • PHARMAMAR
  • PLITIDEPSIN
  • POTENT ANTIVIRAL ACTIVITY
  • VARIANTS

PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19

- The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission - Plitidepsin recently obtained positive results from in vitr...
  • CENTRO NACIONAL DE BIOTECNOLOGíA
  • HEALTHCARE PRODUCTS AGENCY
  • HOSPITAL ADMISSION
  • NATIONAL BIOTECHNOLOGY CENTER
  • PHARMAMAR
  • SPANISH NATIONAL RESEARCH COUNCIL
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com